{Reference Type}: Journal Article
{Title}: GNA14 and GNAQ somatic mutations cause spinal and intracranial extra-axial cavernous hemangiomas.
{Author}: Ren J;Cui Z;Jiang C;Wang L;Guan Y;Ren Y;Zhang S;Tu T;Yu J;Li Y;Duan W;Guan J;Wang K;Zhang H;Xing D;Kahn ML;Zhang H;Hong T;
{Journal}: Am J Hum Genet
{Volume}: 111
{Issue}: 7
{Year}: 2024 07 11
{Factor}: 11.043
{DOI}: 10.1016/j.ajhg.2024.05.020
{Abstract}: Extra-axial cavernous hemangiomas (ECHs) are complex vascular lesions mainly found in the spine and cavernous sinus. Their removal poses significant risk due to their vascularity and diffuse nature, and their genetic underpinnings remain incompletely understood. Our approach involved genetic analyses on 31 tissue samples of ECHs employing whole-exome sequencing and targeted deep sequencing. We explored downstream signaling pathways, gene expression changes, and resultant phenotypic shifts induced by these mutations, both in vitro and in vivo. In our cohort, 77.4% of samples had somatic missense variants in GNA14, GNAQ, or GJA4. Transcriptomic analysis highlighted significant pathway upregulation, with the GNAQ c.626A>G (p.Gln209Arg) mutation elevating PI3K-AKT-mTOR and angiogenesis-related pathways, while GNA14 c.614A>T (p.Gln205Leu) mutation led to MAPK and angiogenesis-related pathway upregulation. Using a mouse xenograft model, we observed enlarged vessels from these mutations. Additionally, we initiated rapamycin treatment in a 14-year-old individual harboring the GNAQ c.626A>G (p.Gln209Arg) variant, resulting in gradual regression of cutaneous cavernous hemangiomas and improved motor strength, with minimal side effects. Understanding these mutations and their pathways provides a foundation for developing therapies for ECHs resistant to current therapies. Indeed, the administration of rapamycin in an individual within this study highlights the promise of targeted treatments in treating these complex lesions.